August 17, 2017

Mr. Michel Vounatsos  
Chief Executive Officer  
Biogen  
601 Pennsylvania Avenue NW  
Washington, DC 20004

Dear Mr. Vounatsos:

We are launching an in-depth investigation to determine why drug companies are dramatically increasing their prices for drugs used to treat Multiple Sclerosis (MS), which is a disease of the central nervous system that often has devastating and disabling effects on patients. We believe no American should be forced to struggle to afford lifesaving medical treatments, especially when drug companies increase prices without warning, cause, or justification.

According to experts, some drug companies appear to be increasing their prices and setting new, higher prices in lockstep with competitors—a strategy known as “shadow pricing.” When a company increases its price or introduces a new, more expensive drug into the market, other companies increase their prices to match—or shadow—these higher prices.

For example, a study on MS drug prices published by the American Academy of Neurology reported that “the dramatic increases in the costs of the first-generation DMTs [disease-modifying therapies] may have been a response to the introduction of competing treatments with higher prices.”¹ The study found:

Why the costs of MS DMTs in the United States have risen so dramatically is uncertain. However, the simplest explanation is that pharmaceutical companies raise prices of new and old MS DMTs in the United States to increase profits and our health care system puts no limits on these increases.²

According to this study, annual sales of MS drugs doubled from $4 billion to nearly $9 billion from 2008 to 2012. At the same time, the cost of the average annual disease-modifying


² Id.
Mr. Michel Vounatsos
Page 2

MS therapy was $16,050 per patient in 2004, while the average annual cost of the disease-modifying therapy interferon increased to more than $60,000 in 2015.³

As the study noted: “Classic economic theory asserts that competition should reduce or stabilize costs for the consumer as more products enter the market.”⁴

Unfortunately, this has not been the case in the MS drug market. The prices of more than a dozen MS therapies have increased sharply in the past decade, nearly in lockstep with new, more expensive entrants into the market.⁵

The MS market also lacks robust competition from the generic market. Currently, the only generic alternative is for the brand drug Copaxone 20 mg, and it is priced at $66,731.⁶ Shortly before this generic was launched, however, the company that sells Copaxone developed a new 40 mg formulation that could be taken less frequently, and it switched approximately 70% of patients to this new formulation—which faces no generic competition.⁷ The generic reportedly captured only 25% to 30% of the 20 mg market by 2015.⁸

Your company’s five MS drugs appear to be following the market’s pricing pattern. Four of your company’s MS drugs have seen at least double-digit percent price increases since they were approved, and one drug has increased in price by nearly 1,000%. Biogen’s newest drug, Zinbryta, was introduced in 2016 at the staggering price of $86,592 per year. By 2017, Biogen’s other four drugs had risen in price to match Zinbryta. The table below shows these price increases.⁹

---

³ Id.
⁴ Id.
⁹ Data in table from National Multiple Sclerosis Society, Access to MS Medications (online at www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Advocacy/2017-PPC-Access-to-MS-Meds-
In order to evaluate the underlying causes of the skyrocketing prices for MS drugs, we request you provide by August 31, 2017, the following information and documents from 2010 to the present:

(1) A list of your company’s profits and expenses that details the sale of each individual MS drug your company currently markets, including, but not limited to:

(a) profit (including operating and net);
(b) sales;
(c) cost of goods sold;
(d) operating cost;
(e) rebates (including commercial, Medicare Part D, and Medicaid rebates);
(f) discounts;
(g) allowances;
(h) coupons;
(i) patient co-pay;
(j) charge backs;
(k) direct selling expenses;
(l) medical affairs;
(m) marketing;
(n) research and development;
(o) Patient Assistance Programs;
(p) taxes; and
(q) any other expenses or costs;

(2) all documents, including internal analyses or memoranda, that have been provided to, or prepared for, your company or your Board of Directors, referring or relating to sales, profits, and pricing strategies for each individual MS drug your company currently markets;

Leavebehind.pdf) (accessed on Aug. 15, 2017) ("Methodology adapted from Hartung et al. We estimated acquisition costs using average wholesale price (AWP) published by First DataBank. AWP reporting was phased out in 2011 and acquisition costs were then estimated using wholesale acquisition cost (WAC) with the conversion AWP = 1.2 x WAC. We applied a 12% discount to AWP, the median discount that state Medicaid programs reimburse pharmacies, to estimate the amount paid to pharmacies by third-party payers.").
(3) all documents and communications relating to any tax deductions or benefits related to patient assistance programs, eligibility requirements and total number of applicants and recipients for each individual MS drug your company currently markets;

(4) all documents and communications concerning any efforts to extend the patent life of any MS drug your company currently markets, including through the development of new drug strengths or formulations;

(5) all documents and communications concerning your company’s use of limited, restricted, or specialty distribution systems for each individual MS drug your company currently markets; and

(6) all agreements, contracts, and communications to or from suppliers, distributors, wholesalers, insurers, pharmacy benefit managers, retail pharmacies, and any other partner in the distribution channel for each individual MS drug your company currently markets.

If you have any questions about this request, please contact Francesca McCrary with Ranking Member Cummings’ staff at (202) 225-5051. Thank you for your consideration.

Sincerely,

Elijah E. Cummings
Ranking Member

Peter Welch
Member of Congress

cc: The Honorable Trey Gowdy, Chairman